Market
First major pharma to announce AI-driven drug approval by end of 2025?
3
Resolution / Starting Odds
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Official press releases from pharmaceutical companies
Story
FDA Releases Draft Guidance on AI in Medical Devices and Drug Development, Authorizing Nearly 1,000 AI-Enabled Devices as of January 15, 2025
Jan 15, 2025, 10:30 PM
The U.S. Food and Drug Administration (FDA) has released draft guidance documents aimed at regulating artificial intelligence (AI) and machine learning (ML) in the medical sector. These guidelines address the integration of AI into healthcare and biomedicine, highlighting the need for adaptive regulatory frameworks as nearly 1,000 AI-enabled medical devices have already been authorized. The draft guidance covers AI applications in medical devices, drug development, and biological products, providing crucial information for manufacturers and sponsors in the pharmaceutical industry. This initiative is expected to transform drug creation and approval processes.
View original story
Similar markets
Pfizer • 25%
Other • 25%
Johnson & Johnson • 25%
Moderna • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Moderna • 25%
Roche • 25%
Other • 25%
Novartis • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Other • 25%
Roche • 25%
Pfizer • 25%
Other • 25%
Moderna • 25%
Pfizer • 25%
Oracle • 25%
Autoimmune diseases • 25%
Cancer treatment • 25%
Bacterial infections • 25%
Viral infections • 25%
Other • 25%
Johnson & Johnson • 25%
Moderna • 25%
Pfizer • 25%
Microsoft • 25%
IBM • 25%
Other • 25%
Google DeepMind • 25%
Pfizer • 25%
Eli Lilly • 25%
Other • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Johnson & Johnson • 25%
Moderna • 25%
Pfizer • 25%